The reading library
Follow the question
that matters to you.
Find original nonhormonal menopause guides, care-service and medicine reviews, and our care comparison. Every article links to supporting sources and related reading.
37 articles available
Provider review
CoreAge Rx nonhormonal menopause review: paroxetine and the actual treatment goal
The advertised oral paroxetine offer, its off-label menopause wording, starting price, and the clinical questions a product page cannot settle.
Comparison
Best nonhormonal menopause care options to compare, with clear limits
A disclosed commercial first position for CoreAge, followed by a comparison of provider scope, exact medicines, follow-up responsibilities and cost units.
Provider review
Midi nonhormonal menopause review: what a care-plan visit includes
Midi explicitly discusses nonhormonal options. Its consultation scope, public treatment summaries and insurance rules still need to be read separately.
Provider review
Evernow nonhormonal menopause review: medicine choices and ongoing care
Official paroxetine and Veozah pages confirm the nonhormonal scope. Check the exact prescription, current safety record and care-access costs before interpreting the offer.
Guide
Non-estrogen medication for hot flashes: understand the treatment families
Separate antidepressant medicines, neurokinin-targeted treatments, other prescriptions and evidence-based non-drug support without ranking them for an individual.
Guide
Fezolinetant and liver monitoring: understand the responsibility behind the tests
What Veozah's current boxed warning adds to a hot-flash treatment discussion, and why a laboratory order needs a clear review and response process.
Guide
Lynkuet vs Veozah: a guide to comparing the evidence
Compare the questions each product raises, read the trial limits and prepare for a discussion about treatment and follow-up.
Guide
Prepare a nonhormonal menopause visit around the result that matters to you
Bring symptom priorities, previous treatment experience and practical follow-up questions without trying to choose a prescription from an online checklist.
Provider review
Alloy nonhormonal menopause review: the product behind the approval claim
Alloy offers paroxetine for hot flashes. Its advertised strength, approval wording and conflicting supply descriptions need to be read together.
Provider review
Gennev nonhormonal menopause review: separate the doctor’s proposal from lifestyle support
Gennev explicitly offers nonhormonal prescriptions alongside dietitian and lifestyle services. Their purposes, evidence and costs should remain distinguishable.
Provider review
MyMenopauseRx nonhormonal menopause review: a named medicine brings additional responsibilities
MyMenopauseRx lists fezolinetant among its options. That specific offer makes the current liver-safety record and responsibility for follow-up important parts of the conversation.
Provider review
Pandia Health nonhormonal menopause review: two named options within a larger care offer
Pandia lists paroxetine and Veozah alongside hormone medicines. The menu, clinical membership and pharmacy transaction answer different questions.
Provider review
Stella nonhormonal menopause review: clinical treatment and app support have different roles
Stella’s US service explicitly includes nonhormonal options, while its app supplies coaching and educational support. One does not establish the evidence or availability of the other.
Provider review
Wisp nonhormonal menopause review: local dryness care is not a hot-flash medicine offer
Wisp has a menopause consultation and a specific hormone-free vaginal moisturizer listing. Those records support different claims and different purchase questions.
Provider review
Joi nonhormonal menopause review: a relevant clinic with an unresolved treatment menu
Joi has an actual menopause clinical service, but the reviewed program centers on hormones. Its wellness language does not confirm a specific nonhormonal hot-flash prescription.
Provider review
FOLX nonhormonal menopause review: clinical care, community and membership are separate
FOLX explicitly offers nonhormonal menopause medicines within LGBTQIA+ care. Its membership, clinical visits and community support should not be treated as one treatment or price.
Provider review
Maven Clinic nonhormonal menopause review: what the two-visit package includes
Maven’s direct Hormone Care offer names nonhormonal medicine families. Its one-time package has defined consultation and messaging limits, with prescriptions and later care separate.
Product review
Veozah review: hot-flash evidence with a liver-safety responsibility
Read the exact fezolinetant tablet record, the placebo comparison and the practical responsibilities that accompany its boxed warning.
Product review
Lynkuet review: original approval evidence and the newer seizure warning
Elinzanetant has a defined hot-flash indication, a placebo-controlled evidence base and current safety information beyond its launch announcement.
Product review
Brisdelle review: the specific paroxetine capsule behind a hot-flash approval
A low-strength capsule has a defined menopausal indication, distinct trial findings and SSRI precautions that a generic ingredient reference can obscure.
Provider review
Allara nonhormonal menopause review: symptom care, nutrition and plan-price differences
Allara includes menopause in its clinical scope, but its broader care program, treatment evidence and conflicting price displays require separate reading.
Provider review
Hello Alpha nonhormonal menopause review: separate the symptom menu from the prescription
The service names antidepressants and gabapentin, while its local-cream wording, membership allowance and refill terms need close attention.
Provider review
Myla Health nonhormonal menopause review: a UK discussion with explicit follow-up boundaries
Myla’s consultation, NHS handoff limits and responsibility for outside investigations matter when hormone avoidance is only the starting question.
Provider review
Newson Clinic nonhormonal menopause review: what the consultation page actually promises
A UK clinic explicitly includes nonhormonal options in discussion; that statement still leaves the medicine, jurisdiction and complete care costs to identify.
Provider review
Mass General Brigham nonhormonal menopause review: coordinating a regional symptom assessment
The Menopause and Midlife Clinic offers an actual clinical route; its breadth should not be confused with a verified medication menu or an all-inclusive price.
Provider review
Penn Medicine nonhormonal menopause review: what needs current confirmation
Our September 29 service description is historical. Current scope, appointment routing and eligibility need confirmation before arranging care.
Provider review
Duke Health nonhormonal menopause review: define the hot-flash goal before interpreting the drug family
Duke discusses low-dose antidepressants for hot flashes, night sweats and sleep disturbance. The family name does not identify a prescription, diagnose depression or settle the safety review.
Provider review
Cleveland Clinic nonhormonal menopause review: hot flashes and vaginal discomfort are different goals
Cleveland describes nonhormonal hot-flash medicines and over-the-counter vaginal lubricants. These are different treatment discussions, with individual medication decisions separate from a shared appointment.
Provider review
Mayo Clinic nonhormonal menopause review: choose the consultation goal before naming a treatment
Mayo’s Minnesota clinic separates menopause, sexual-health and cancer-survivorship consultations. Nonhormonal options are a documented discussion topic, not one medicine for every concern.
Provider review
Johns Hopkins nonhormonal menopause review: a coordinated assessment comes before the medication category
Hopkins offers referral-based menopause care and discussion of several treatment approaches. Its public clinic page does not identify a nonhormonal medicine or promise a particular remote prescription.
Provider review
Mount Sinai nonhormonal menopause review: symptom research is different from a treatment offer
Mount Sinai documents clinical menopause care and research about differences in hot flashes. Those records do not identify an exact nonhormonal prescription or prove that a newer medicine is available there.
Provider review
Northwestern Medicine nonhormonal menopause review: therapy roles should follow the concern
Northwestern lists nonhormonal options, pelvic-floor therapy and talk therapy for specified concerns. A broad menu does not make every form of support a proven treatment for hot flashes.
Provider review
UCLA Health nonhormonal menopause review: sleep concerns need their own treatment question
UCLA’s multidisciplinary service includes sleep, cognition and mood. Those assessment areas do not establish a named nonhormonal prescription or turn a hot-flash medicine into an insomnia treatment.
Provider review
Stanford Health Care nonhormonal menopause review: a named option still needs its own safety plan
Stanford names fezolinetant, gabapentin and antidepressants. The current fezolinetant label adds an essential boundary to that treatment menu: liver risk, contraindications and accountable monitoring.
Provider review
University of Utah Health nonhormonal menopause review: a broad care menu needs a defined outcome
Utah combines nonhormonal therapies with behavioral, sexual-health and wellness services. A named program is not proof that every listed approach treats hot flashes or fits every medical history.
Guide
Paroxetine’s Menopause Trials: Reading Hot-Flash and Sleep Outcomes Together
Two placebo-controlled trials support a specific hot-flash benefit, while a secondary analysis found modest improvements in symptom-attributed awakenings and sleep duration. Those findings answer a different question from fezolinetant’s research program.
Guide
SKYLIGHT 1: Fezolinetant’s Symptom Effects and Evolving Liver-Safety Evidence
The 527-participant trial established a placebo-adjusted symptom benefit over 12 weeks. Its findings answer a different question from paroxetine’s sleep analyses—and must now be read alongside VEOZAH’s boxed liver warning.